HK Stock Market Move | IMMUNEONCO-B(01541) rose over 3% in early trading, and has initiated the phase II clinical trial IMM27M.

IMMUNEONCO-B (01541) rose more than 3% in the morning session, up 3.31% to HK$8.75 as of press time, with a turnover of HK$4.9034 million. On the news front, IMMUNEONCO-B announced that the company has initiated a phase II clinical trial of IMM27M for the treatment of estrogen receptor-positive (ER+) advanced breast cancer after endocrine therapy failure or recurrence and has recruited the first patient. In addition, the phase I dose escalation study of IMM27M was completed at the end of 2023, with the following results (as of August 6, 2024): a total of eight evaluable ER+ advanced or metastatic breast cancer patients were recruited in the phase I trial. Among them, two patients achieved partial responses (PR) and four patients had stable disease (SD), with an overall response rate (ORR) of 25.0% and disease control rate (DCR) of 75.0%; showing a positive efficacy signal. IMM27M was also shown to be safe and well-tolerated, with no dose-limiting toxicities observed at the highest dose explored in the phase I study of 7.5 mg/kg.